MMMax I. Myers
Max I. Myers
*This is an algorithmically generated author record based on publicly available information.
Research Interests
Max I. Myers has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrew M. Stern
Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA
13 shared publications Brian Golbourn
13 shared publications- D. Lansing Taylor
Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
13 shared publications - Daniel R. Premkumar
Department of Neurosurgery University of Pittsburgh School of Medicine PA USA
13 shared publications Esther P. Jane
13 shared publications- Ian F. Pollack
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
13 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
Supplemental Figure 1. Schematic of the approach taken to achieve drug resistance.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
Supplemental Figure 1. Schematic of the approach taken to achieve drug resistance.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
Supplemental File 1: Differential Gene Expression between drug naive versus resistant/"recovery" U87 cell line
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
Supplemental File 1: Differential Gene Expression between drug naive versus resistant/"recovery" U87 cell line